{"disease":{"id":"adjuvant-treatment-of-early-breast-cancer","name":"adjuvant treatment of early breast cancer"},"drugs":{"marketed":[{"drug_id":"lee011","indication_name":"Adjuvant treatment of early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Kisqali","generic_name":"LEE011","company_name":"Novartis","drug_phase":"marketed","molecular_target":"Cyclin-dependent kinase 4","drug_class":"Kinase Inhibitor","quality_score":66,"revenue":"3600","mechanism":"Kisqali works by blocking a protein called cyclin-dependent kinase 4, which helps cancer cells grow and divide."},{"drug_id":"chembl-chembl1444","indication_name":"Adjuvant treatment of early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"LETROZOLE","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"Aromatase Inhibitor [EPC]","quality_score":18,"revenue":null,"mechanism":null},{"drug_id":"chembl-chembl1444","indication_name":"Extended adjuvant treatment of early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"LETROZOLE","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"Aromatase Inhibitor [EPC]","quality_score":18,"revenue":null,"mechanism":null},{"drug_id":"letrozole-tablets","indication_name":"Adjuvant Treatment of Early Breast Cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Letrozole tablets","company_name":"Al-Azhar University","drug_phase":"marketed","molecular_target":"","drug_class":"Aromatase Inhibitor [EPC]","quality_score":21,"revenue":null,"mechanism":null},{"drug_id":"letrozole-tablets","indication_name":"Extended Adjuvant Treatment of Early Breast Cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Letrozole tablets","company_name":"Al-Azhar University","drug_phase":"marketed","molecular_target":"","drug_class":"Aromatase Inhibitor [EPC]","quality_score":21,"revenue":null,"mechanism":null},{"drug_id":"chembl-chembl3545110","indication_name":"Adjuvant treatment of early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"RIBOCICLIB","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":25,"revenue":null,"mechanism":null},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of breast cancer in postmenopausal women with hormone receptor-positive early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"anastrozole","indication_name":"Adjuvant treatment of early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Arimidex","generic_name":"anastrozole","company_name":"AstraZeneca","drug_phase":"marketed","molecular_target":"Aromatase enzyme","drug_class":"Aromatase inhibitor","quality_score":68,"revenue":null,"mechanism":"Anastrozole selectively inhibits aromatase enzyme, suppressing estrogen biosynthesis in postmenopausal breast cancer."},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":64,"totalPipeline":0},"trials":{"data":[],"total":0},"guidelines":[{"drug_id":"letrozole","guideline_body":"FDA label","recommendation":"Femara (letrozole) is indicated for the adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer.","line_of_therapy":"adjuvant","evidence_grade":"not specified","guideline_year":null},{"drug_id":"anastrozole","guideline_body":"FDA label","recommendation":"Anastrozole tablets are indicated for adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer.","line_of_therapy":"adjuvant","evidence_grade":"N/A","guideline_year":null}],"source":"Drug Landscape verified database"}